The global asthma & COPD therapies market was valued at $32bn in 2018 and is projected to grow at a CAGR of 6.0% in the first half of the forecast period. In 2018, the combination drugs segment held 39% of the global asthma & COPD market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 309-page report you will receive 112 tables and 131 figures– all unavailable elsewhere.
The 309-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Asthma & COPD Therapies Market forecasts from 2019-2029, further broken down into:
• Global Asthma Therapies Market forecasts
• Global COPD Therapies Market forecasts
• Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
• Bronchodilators monotherapy
• Anti-inflammatory drugs
• Combination drugs
• Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
• Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
• Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
• Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris
• Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
• Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
• Anti-leukotrienes: Singulair
• Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
• Revenue forecast for the Combination drugs market and the leading drugs:
• Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo
• This report provides individual revenue forecasts from 2019-2029 for these regional and national markets:
• The US
• Japan
• EU5: Germany, France, UK, Italy, Spain
• BRIC: Brazil, Russia, India, China
• Mexico
• Other Countries
• This report discusses the leading companies in the global asthma & COPD therapies market:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva
• This report discusses drugs currently in clinical development for treating asthma and COPD.
• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.
Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.
Buy our report today Asthma & COPD Therapies Market Analysis : Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Classifying Respiratory Diseases: Obstructive and Restrictive
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
3. Asthma and COPD Therapies: Global Market 2019-2029
3.1 The Global Respiratory Drugs Market by Therapeutic Area
3.2 The Global Asthma and COPD Therapies Market in 2018
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2017-2029
3.3.1 Global Asthma Therapies Market: Sales Forecast, 2017-2029
3.3.2 Global COPD Therapies Market: Sales Forecast 2017-2029
3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2017-2029
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Shares Change to 2029
3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2017-2029
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Bronchodilator Monotherapy Market 2019-2029
4.1 Introduction to Bronchodilator Monotherapy
4.2 The Bronchodilator Monotherapy Market in 2017
4.2.1 Leading Bronchodilators in 2017
4.2.2 Bronchodilator Monotherapy: Market Forecast 2019-2029
4.2.3 How Will Market Shares by Drug Class Change to 2029?
4.3 The Anticholinergics Market 2019-2029
4.3.1 Leading Anticholinergics in 2017
4.3.2 Anticholinergics: Market Forecast 2019-2029
4.3.3 Market Share of Leading Anticholinergics to 2029
4.3.4 Spiriva (tiotropium - Boehringer Ingelheim)
4.3.4.1 Spiriva: Sales Forecast 2019-2029
4.3.4.2 Spiriva: Recent Developments
4.3.5 Atrovent (ipratropium, Boehringer Ingelheim)
4.3.5.1 Atrovent: Sales Forecast 2019-2029
4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini)
4.3.6.1 Eklira/Tudorza/Bretaris: Sales Forecast 2017-2029
4.4 The SABAs Market 2019-2029
4.4.1 Leading SABAs in 2017
4.4.2 SABAs: Market Forecast 2019-2029
4.4.3 Market Share of Leading SABAs to 2029
4.4.4 Ventolin (salbutamol, GSK)
4.4.4.1 Ventolin: Sales Forecast 2019-2029
4.4.5 ProAir (salbutamol, Teva)
4.4.5.1 ProAir: Sales Forecast 2019-2029
4.4.6 Proventil (salbutamol, Merck)
4.4.6.1 Proventil: Sales Forecast 2019-2029
4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
4.4.7.1 Xopenex: Sales Forecast 2019-2029
4.5 The Long-Acting Beta2-Agonist (LABA) Market 2017-2029
4.5.1 Leading LABAs in 2017
4.5.2 LABAs: Market Forecast 2019-2029
4.5.3 Market Share of Leading LABAs to 2029
4.5.4 Foradil (formoterol, Merck/Novartis)
4.5.4.1 Foradil: Sales Forecast 2017-2029
4.5.5 Brovana (arfomoterol, Dainippon Sumitomo)
4.5.5.1 Brovana: Sales Forecast 2017-2029
4.5.6 Arcapta/Onbrez (indacaterol, Novartis)
4.5.6.1 Arcapta/Onbrez: Sales Forecast 2017-2029
4.5.7 Serevent (salmeterol, GSK)
4.5.7.1 Serevent: Sales Forecast 2017-2029
5. Anti-inflammatory Drugs Market 2019-2029
5.1 Introduction to Anti-Inflammatory Drugs
5.2 The Anti-Inflammatory Drugs Market in 2017
5.2.1 Leading Anti-Inflammatory Drugs in 2017
5.2.2 Anti-Inflammatory Drugs: Market Forecast 2019-2029
5.2.3 How Will Market Shares by Drug Class Change to 2029?
5.3 The Corticosteroids Market 2019-2029
5.3.1 Leading Corticosteroids in 2017
5.3.2 Corticosteroids: Market Forecast 2019-2029
5.3.3 Market Share of Leading Corticosteroids to 2029
5.3.4 Flixotide/Flovent (fluticasone propionate, GSK)
5.3.4.1 Flixotide/Flovent: Sales Forecast 2019-2029
5.3.5 Pulmicort (budesonide, AstraZeneca)
5.3.5.1 Pulmicort: Sales Forecast 2019-2029
5.3.6 QVAR (beclometasone, Teva)
5.3.6.1 QVAR: Sales Forecast 2017-2029
5.3.7 Asmanex (mometasone, Merck)
5.3.7.1 Asmanex: Sales Forecast 2019-2029
5.4 The Anti-Leukotrienes Market 2019-2029
5.4.1 Leading Anti-Leukotrienes in 2017
5.4.2 Anti-Leukotrienes: Market Forecast 2019-2029
5.4.3 Market Share of Leading Anti-Leukotrienes to 2029
5.4.4 Singulair (montelukast, Merck)
5.4.4.1 Singulair: Sales Forecast 2017-2029
5.5 The Monoclonal Antibodies Market 2019-2029
5.5.1 Monoclonal Antibodies: Market Forecast 2019-2029
5.5.2 Market Share of Leading Monoclonal Antibodies to 2029
5.5.3 Xolair (omalizumab, Novartis/Roche)
5.5.3.1 Xolair: Sales Forecast 2019-2029
5.5.4 Cinquil/Cinquair (reslizumab, Teva)
5.5.4.1 Cinquil: Sales Forecast 2019-2029
5.5.5 Nucala (Mepolizumab, GSK)
5.5.5.1 Nucala: Sales Forecast 2019-2029
5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
5.5.6.1 Benralizumab: Sales Forecast 2019-2029
5.5.7 Lebrikizumab (RG3637, Roche)
5.5.7.1 Lebrikizumab: Sales Forecast 2019-2029
5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
5.5.8.1 Dupilumab: Sales Forecast 2017-2029
6. Combination Drugs Market 2019-2029
6.1 Introduction to Combination Drugs
6.1.1 Leading Combination Drugs in 2017
6.1.2 Combination Drugs: Market Forecast 2017-2029
6.1.3 How Will Market Shares by Drug Change to 2029?
6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK)
6.1.4.1 Advair/Seretide: Sales Forecast 2017-2029
6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
6.1.5.1 Symbicort: Sales Forecast 2017-2029
6.1.5.2 Symbicort: The SMART Concept
6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
6.1.6.1 Combivent: Sales Forecast 2017-2029
6.1.7 Dulera (formoterol/mometasone, Merck)
6.1.7.1 Dulera: Sales Forecast 2017-2029
6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
6.1.8.1 Breo/Relvar: Sales Forecast 2017-2029
6.2 Recently Launched Combination Drugs
7. Leading National Markets 2017-2029
7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market
7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2017-2029
7.2.1 How Will Regional Market Shares Change to 2029?
7.2.2 National Breakdown of the Global Asthma and COPD Therapies Market
7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2017-2029
7.2.4 How Will National Market Shares Change to 2029?
7.3 The US Asthma and COPD Therapies Market 2017-2029
7.3.1 The US Asthma and COPD Therapies Market Forecast 2017-2029
7.3.2 US Asthma and COPD Therapies Market Trends and Developments
7.3.2.1 Increasing COPD Prevalence in the US
7.3.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
7.3.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
7.4 Japanese Asthma and COPD Therapies Market 2017-2029
7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2017-2029
7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
7.4.2.1 Is Generic Penetration to Reach 60% by 2018?
7.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform
7.5 EU5 Asthma and COPD Therapies Market 2017-2029
7.5.1 German Asthma and COPD Therapies Market Forecast 2017-2029
7.5.2 French Asthma and COPD Therapies Market Forecast 2017-2029
7.5.3 UK Asthma and COPD Therapies Market Forecast 2017-2029
7.5.4 Italian Asthma and COPD Therapies Market Forecast 2017-2029
7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2017-2029
7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
7.5.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
7.5.6.2 France: Social Security Finance Bill 2015
7.5.6.3 UK: Improving Asthma and COPD Patient Outcomes
7.5.6.4 Italy: Austerity Measures Limiting Growth
7.5.6.5 Spain: The Start of Recovery in the Spanish Economy
7.6 BRIC Asthma and COPD Therapies Market 2017-2029
7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2017-2029
7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
7.6.2.1 China’s Industrial Future and Asthma/COPD
7.6.2.2 Expansion of Healthcare Coverage and Reimbursement
7.6.2.3 Price Controls and the Anhui Model
7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2017-2029
7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
7.6.4.1 Increasing Access to Medicines
7.6.5 Indian Asthma and COPD Therapies Market Forecast 2017-2029
7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments
7.6.6.1 Drug Prices Control Order 2013
7.6.6.2 Expansion of Healthcare Provision
7.6.7 Russian Asthma and COPD Therapies Market Forecast 2017-2029
7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments
7.6.8.1 No Embargo on Foreign Drug Imports
7.6.8.2 Pharma2021 and the Russian Pharmaceutical Industry
7.7 Mexican Asthma and COPD Therapies Market 2017-2029
7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2017-2029
7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
7.7.2.1 Seguro Popular: Mexican Healthcare Reform
7.7.2.2 COFEPRIS: Regulatory Changes and Improvements
7.7.2.3 Mexico’s Agreement for Innovation
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.2 Leading Companies in Asthma and COPD in 2017
8.3 Leading Companies: Market Forecast 2017-2029
8.4 How Will Leading Companies’ Market Shares Change to 2029?
8.5 GSK
8.5.1 GSK: Asthma and COPD Therapies
8.5.2 GSK: Sales Forecast 2017-2029
8.5.3 GSK: Products in Development
8.5.4 GSK: Recent Developments
8.5.4.1 Recently Launched Combination Drugs
8.5.4.2 GSK Divests OTC Products
8.5.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.6.2 Boehringer Ingelheim: Sales Forecast 2017-2029
8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.6.4 Boehringer Ingelheim: Recent Developments
8.6.4.1 Expansion of Respimat Manufacturing Capacity
8.6.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.6.4.3 Ben Venue Laboratories Shut Down
8.6.4.4 Sale of Roxane Laboratories
8.6.4.5 Spiloto Respimat and the PHYSACTO Study
8.7 AstraZeneca
8.7.1 AstraZeneca: Asthma and COPD Therapies
8.7.2 AstraZeneca: Sales Forecast 2017-2029
8.7.3 AstraZeneca: Products in Development
8.7.4 AstraZeneca: Recent Developments
8.7.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.7.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug Pipeline
8.7.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.7.4.4 AstraZeneca Acquires Right to Actavis’ Branded Respiratory Portfolio in US and Canada
8.7.4.5 Takeda Respiratory Portfolio Acquisition
8.8 Merck & Co. (Merck)
8.8.1 Merck: Asthma and COPD Therapies
8.8.2 Merck: Sales Forecast 2017-2029
8.8.3 Merck: Products in Development
8.8.4 Merck: Recent Developments
8.8.4.1 Bayer Acquires Merck’s Consumer Health Business
8.8.4.2 FDA Rejects Singulair OTC Switch
8.8.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.9 Novartis
8.9.1 Novartis: Asthma and COPD Therapies
8.9.2 Novartis: Sales Forecast 2017-2029
8.9.3 Novartis: Products in Development
8.9.4 Novartis: Recent Developments
8.9.4.1 Novartis Restructures Following Strategic Review
8.9.4.2 Novartis Presents Data on Ultibro and Seebri
8.9.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.10 Roche
8.10.1 Roche: Asthma and COPD Therapies
8.10.2 Roche: Sales Forecast 2017-2029
8.10.3 Roche: Products in Development
8.11 Teva
8.11.1 Teva: Asthma and COPD Therapies
8.11.2 Teva: Sales Forecast 2017-2029
8.11.3 Teva: Products in Development
8.11.4 Teva: Recent Developments
8.11.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2017-2029
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 AZD8871 (MABA, AstraZeneca)
9.2.1.2 GSK961081 (Batefenterol, GSK)
9.2.1.3 LAS100977 (Abediterol, AstraZeneca)
9.2.1.4 QVAR BAI (beclometasone, Teva)
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 mepolizumab (IL-5 receptor antagonist, GSK)
9.3.1.2 benralizumab (IL-5 receptor antagonist, AstraZeneca)
9.3.1.3 tralokinumab (IL-13 receptor antagonist, AstraZeneca)
9.3.1.4 QAW039 (fevipiprant, Novartis)
9.3.1.5 Lebrikizumab (IL-13 receptor antagonist, Roche)
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 fluticasone furoate & vilanterol & umeclidinium (GSK)
9.4.1.2 PT010 (long-acting muscarinic antagonist (LAMA) glycopyrronium, the long acting β2-agonist (LABA) formoterol fumarate and budesonide, an inhaled corticosteroid (ICS), AstraZeneca)
9.4.1.3 QMF149 (indacaterol, mometasone furoate, Novartis)
9.4.1.4 QVM149 (indacaterol, glycopyrronium, mometasone, Novartis)
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2017-2029
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.3 Ultra-Long-Acting Beta2-Agonists
10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.5 Monoclonal Antibodies
10.4.6 LAMA/LABA Combinations
10.4.7 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
11. Conclusions
11.1 Asthma and COPD Therapies: A Maturing Market
11.2 The Global Asthma and COPD Therapies Market in 2017
11.3 Current Leading Asthma and COPD Therapies Segments
11.3.1 Leading Asthma and COPD Therapies
11.3.2 Leading Asthma and COPD Therapies Companies
11.4 Leading Regional and National Markets
11.5 Global Asthma and COPD Therapies Market Forecast 2017-2029
11.6 The Future of the Asthma and COPD Therapies Market
11.6.1 Growth in Anti-Inflammatory and Combination Drugs
11.6.2 Personalised Medicine
11.6.3 Unmet Needs in Asthma and COPD
11.7 Strategies for Growth in 2017-2029
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 Classification of Respiratory Diseases, 2018
Table 2.2 Causes of Asthma, 2018
Table 2.3 Triggers of Asthma, 2018
Table 2.4 Clinical Trial Phases
Table 3.1 Global Asthma & COPD Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2018
Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2017
Table 3.3 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2018, 2023 and 2029
Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2018
Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2017
Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2017
Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018, 2023 and 2029
Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.10 Leading SABAs in 2017
Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 4.12 SABAs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2017
Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2017, 2023 and 2029
Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2017
Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2017
Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2017-2029
Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2023 and 2029
Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2017
Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2017, 2023 and 2029
Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2017
Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2017, 2023 and 2029
Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017, 2023 and 2029
Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2017
Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2017, 2023 and 2029
Table 6.4 GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2017
Table 7.2 Global Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2017-2029
Table 7.3 Leading Regional Asthma and COPD Therapies Market: Market Share (%) 2018, 2023 and 2029
Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2018
Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2018, 2023 and 2029
Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2017-2029
Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2029
Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2017
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2017-2029
Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2017, 2023 and 2029
Table 8.4 GSK: Overview
Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
Table 8.7 GSK: Asthma and COPD Therapies Pipeline
Table 8.8 Boehringer Ingelheim: Overview
Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 8.11 AstraZeneca: Overview
Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2017-2029
Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline
Table 8.15 Merck: Overview
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
Table 8.18 Novartis: Overview
Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
Table 8.21 Novartis: Asthma and COPD Therapies Pipeline
Table 8.22 Roche: Overview
Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
Table 8.24 Teva: Overview
Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2017
Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2017-2029
Table 8.27 Teva: Asthma and COPD Therapies Pipeline
List of Figures
Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2018
Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2018
Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2018
Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2018
Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2018
Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2017
Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2018
Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2023
Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2029
Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2017-2029
Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2018
Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2023
Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2029
Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2018
Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2023
Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2029
Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2017-2029
Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2017-2029
Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2017-2029
Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2018
Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2023
Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2029
Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2017-2029
Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2017-2029
Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2017-2029
Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2017-2029
Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2018
Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2023
Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2029
Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2017-2029
Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2017-2029
Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2017-2029
Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2017-2029
Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2017
Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2017
Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2023
Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2023
Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2029
Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2029
Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2017
Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2023
Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2029
Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2017-2029
Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2017-2029
Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2017-2029
Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2017-2029
Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2018
Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2023
Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2029
Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2017-2029
Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2017
Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2023
Figure 5.24 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2029
Figure 5.25 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2017-2029
Figure 5.26 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2017-2029
Figure 5.27 GSK: Nucala Revenue ($m) and AGR (%), 2017-2029
Figure 5.28 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2017-2029
Figure 5.29 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2017-2029
Figure 5.30 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2017-2029
Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2017-2029
Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2017
Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2023
Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2029
Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2017-2029
Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2017-2029
Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2017-2029
Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2017-2029
Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2017-2029
Figure 7.1 Global Asthma and COPD Therapies Market: Revenues ($m) by Region, 2017
Figure 7.2 Global Asthma and COPD Therapies Market: Market Shares (%) by Region, 2017
Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2017-2029
Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2023
Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2029
Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2018
Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2018
Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2023
Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2029
Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and 2017-2029
Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2017-2029
Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027
Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2017-2029
Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2017
Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2017
Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2023
Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2023
Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2029
Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2029
Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2017
Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2017
Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2017-2029
Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2017-2029
Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2017-20279
Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2017-2029
Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2017-2029
